Screener
MoonLake Immunotherapeutics MLTX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | March 31, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Current liabilities | ||
| Trade and other payables | $23,380 | $29,553 |
| Accrued expenses and other current liabilities | 21,814 | 14,691 |
| Short-term portion of operating lease liabilities | 920 | 1,234 |
| Total current liabilities | 46,114 | 45,478 |
| Non-current liabilities | ||
| Long-term debt | 99,018 | 74,100 |
| Long-term portion of operating lease liabilities | 865 | 374 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's operating lease liabilities (current)?
- MoonLake Immunotherapeutics (MLTX) reported operating lease liabilities (current) of $920K in Q1 2026.
- How has MoonLake Immunotherapeutics's operating lease liabilities (current) changed year-over-year?
- MoonLake Immunotherapeutics's operating lease liabilities (current) decreased by 35.8% year-over-year, from $1.43M to $920K.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about MoonLake Immunotherapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude